Dafaglifazone
Searching the Web
dapagliflozin 2025 2026 clinical updates indications
Searching PubMed
dapagliflozin
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Here is a thorough summary of Dapagliflozin (Farxiga), compiled from authoritative medical textbooks and recent evidence:
Dapagliflozin (Farxiga)
Drug Class
Sodium-glucose cotransporter 2 (SGLT2) inhibitor - an oral antihyperglycemic agent.
Mechanism of Action
SGLT2 is responsible for reabsorbing approximately 90% of filtered glucose in the proximal renal tubule. Dapagliflozin selectively inhibits SGLT2, which:
- Decreases reabsorption of glucose from the tubular lumen
- Increases urinary glucose excretion (glycosuria)
- Causes natriuresis and osmotic diuresis, lowering blood pressure modestly
- Promotes weight loss
This mechanism is entirely independent of insulin and blood glucose levels do not need to be elevated for the drug to act.
- Lippincott Illustrated Reviews: Pharmacology
FDA-Approved Indications
| Indication | Notes |
|---|---|
| Type 2 diabetes mellitus | Glycemic control in adults |
| Heart failure with reduced ejection fraction (HFrEF) | With or without T2DM |
| Heart failure with preserved ejection fraction (HFpEF) | Approved based on DELIVER trial data |
| Chronic kidney disease (CKD) | Including non-diabetic CKD (DAPA-CKD trial) |
Key Clinical Trials
DAPA-HF (2019) - HFrEF
- 4,744 patients with LVEF ≤40%, NYHA class II-IV
- 18-month follow-up
- Dapagliflozin reduced the composite of worsening HF or CV mortality by 26% vs. placebo
- Reduced CV mortality, HF hospitalizations, and all-cause mortality
- Benefit was seen regardless of type 2 diabetes status
- Fuster and Hurst's The Heart, 15th Ed.
DAPA-CKD
- Patients with eGFR 25-75 mL/min/1.73 m² (including non-diabetics)
- Dapagliflozin reduced sustained ≥50% eGFR decline, ESKD, and kidney/CV death
- Also reduced HF hospitalizations and CV death as secondary endpoints
- Comprehensive Clinical Nephrology, 7th Ed.
DAPA ACT HF-TIMI 68 (2025, PMID 40884036)
- Recent RCT + meta-analysis examining dapagliflozin in hospitalized HF patients
- Published November 2025 in Circulation
Pharmacokinetics
- Given once daily in the morning (no dose titration required)
- Metabolized primarily by glucuronidation to inactive metabolites
- Minimal drug-drug interactions
- Should be avoided in severe renal dysfunction (eGFR <25 mL/min/1.73 m²); note that at lower eGFR ranges (25-45), glucose-lowering efficacy is reduced but cardiorenal benefit persists
- Lippincott Illustrated Reviews: Pharmacology
Advantages in Heart Failure
SGLT2 inhibitors like dapagliflozin have several unique advantages:
- Once-daily dosing - no titration needed
- Minimal drug-drug interactions
- Osmotic diuresis + natriuresis - synergistic with loop diuretics, but with less compensatory RAAS activation (preferentially reduces interstitial volume, not intravascular volume)
- Renoprotective - reduces CKD progression
- Fuster and Hurst's The Heart, 15th Ed.
Adverse Effects
| Effect | Details |
|---|---|
| Genital mycotic infections | Vulvovaginal candidiasis most common |
| Urinary tract infections | Increased frequency |
| Urinary frequency | Due to osmotic diuresis |
| Hypotension | Especially in elderly or patients on diuretics; check volume status before starting |
| Diabetic ketoacidosis (DKA) | Can occur at near-normal glucose levels ("euglycemic DKA") |
| Fournier's gangrene | Rare but serious perineal infection; FDA warning issued 2018 |
| Bone fractures | Increased risk |
Contraindications / Cautions
- Severe renal dysfunction (eGFR <25 mL/min/1.73 m²) - avoid
- eGFR <45 mL/min/1.73 m² - not licensed for glucose-lowering (though cardiorenal benefit persists down to eGFR 25 in CKD trials)
- Risk factors for ketoacidosis: alcohol use, caloric restriction, perioperative period
2026 Guideline Update
NICE (2026) now recommends SGLT2 inhibitors including dapagliflozin alongside metformin as first-line treatment for type 2 diabetes in most patients, a major shift from the prior "metformin first, add-on later" approach. NICE analysis projects this could prevent ~17,000 deaths over 3 years through cardiovascular and renal protection. For CKD with eGFR 20-30, dapagliflozin or empagliflozin combined with a DPP-4 inhibitor is recommended.
Recent Evidence (2024-2026)
- PMID 40556828 - Network meta-analysis: SGLT2 inhibitors vs. GLP-1 agonists vs. sulfonylureas in T2DM with HF (2025)
- PMID 40324721 - Network meta-analysis: Comparative efficacy of SGLT2 inhibitor class members in HF + T2DM (2025)
- PMID 40884036 - DAPA ACT HF-TIMI 68 RCT + meta-analysis: Dapagliflozin in hospitalized HF (Circulation, 2025)
This is a shared conversation. Sign in to Orris to start your own chat.